<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00411138</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000521447; P06.031</org_study_id>
    <secondary_id>CKTO-2006-04</secondary_id>
    <secondary_id>ISRCTN14387080</secondary_id>
    <secondary_id>P06.031-PORTEC-3</secondary_id>
    <secondary_id>2007-004917-33</secondary_id>
    <nct_id>NCT00411138</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer</brief_title>
  <acronym>PORTEC-3</acronym>
  <official_title>Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy With Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma: PORTEC-3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Australia New Zealand Gynaecological Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work
      in different ways to stop the growth of tumor cells, either by killing the cells or by
      stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells.
      Giving chemotherapy and radiation therapy after surgery may kill any tumor cells that remain
      after surgery. It is not yet known whether giving chemotherapy together with radiation
      therapy is more effective than giving radiation therapy alone in treating endometrial cancer.

      PURPOSE: This randomized phase III trial is studying chemotherapy and radiation therapy to
      see how well they work compared with radiation therapy alone in treating patients with
      high-risk, stage I, stage II, or stage III endometrial cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the overall survival and failure-free survival of patients with high-risk stage
           IB-III endometrial carcinoma treated with concurrent chemoradiotherapy followed by
           adjuvant chemotherapy vs pelvic radiotherapy alone.

      Secondary

        -  Compare the rates of pelvic and distant recurrence, severe (grades 3 and 4)
           treatment-related toxicity, and quality of life of patients treated with these regimens.

      OUTLINE:

      This is a multicenter, prospective, open-label, randomized, controlled study. Patients are
      stratified according to participating group (DGOG vs UK NCRI vs NCIC CTG vs MaNGO vs
      Unicancer), type of surgery (total abdominal hysterectomy and bilateral salpingo-oophorectomy
      [TAH-BSO] vs TAH-BSO plus lymphadenectomy vs laparoscopic hysterectomy [TLH-BSO] vs TLH-BSO
      plus lymphadenectomy), stage (IA vs IB vs II vs III), and histological type (endometrioid
      carcinoma vs serous or clear cell carcinoma). Patients are randomized to 1 of 2 treatment
      arms.

        -  Arm I: Patients receive external-beam pelvic radiotherapy 5 days a week for up to 6
           weeks, combined with cisplatin IV days 1 and 22. Patients with cervical involvement
           undergo vaginal brachytherapy boost. At least 3 weeks after completion of
           chemoradiotherapy, patients undergo adjuvant chemotherapy comprising paclitaxel IV and
           carboplatin IV on day 1. Adjuvant chemotherapy repeats every 3 weeks for up to 4 courses
           in the absence of disease progression or unacceptable toxicity.

        -  Arm II: Patients undergo external-beam pelvic radiotherapy (and vaginal brachytherapy
           alone in case of cervical involvement) as in arm I.

      Quality of life is assessed at baseline, completion of radiotherapy, completion of
      chemotherapy, at 6 months, and then once a year for 5 years.

      After completion of study therapy, patients are followed periodically for up to 10 years.

      PROJECTED ACCRUAL: A total of 670 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 23, 2006</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">April 1, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>co-primary endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Failure-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>co-primary endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life by QLQ-C30 v3.0</measure>
    <time_frame>5 years</time_frame>
    <description>Health-related overall quality of life and patient-reported symptom measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe treatment-related morbidity</measure>
    <time_frame>5 years</time_frame>
    <description>Acute serious events and SAE and late grade 3-4 complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal or pelvic relapse</measure>
    <time_frame>5 years</time_frame>
    <description>Both vaginal or pelvic relapse as first failure and total vaginal or pelvic relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastases</measure>
    <time_frame>5 years</time_frame>
    <description>Both distant relapse as first failure and total distant relapse</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">670</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Radiation Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pelvic Radiotherapy alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiation Therapy and Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pelvic Radiation plus 2 concurrent cycles cisplatin followed by 4 adjuvant cycles carboplatin and paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>External beam pelvic radiotherapy (48.6 Gy in 1.8 Gy fractions) Vaginal brachytherapy boost in case of cervical involvement</description>
    <arm_group_label>Radiation Therapy</arm_group_label>
    <arm_group_label>Radiation Therapy and Chemotherapy</arm_group_label>
    <other_name>RT</other_name>
    <other_name>3D conformal radiotherapy</other_name>
    <other_name>IMRT</other_name>
    <other_name>brachytherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>cisplatin 50 mg/m2 i.v., 2 cycles during radiotherapy, 3 wks interval</description>
    <arm_group_label>Radiation Therapy and Chemotherapy</arm_group_label>
    <other_name>Cisplatine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>carboplatin AUC 5, 4 cycles after completion of radiotherapy, 3 wks interval</description>
    <arm_group_label>Radiation Therapy and Chemotherapy</arm_group_label>
    <other_name>Carboplatine</other_name>
    <other_name>Carbotaxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>paclitaxel 175 mg/m2, 4 cycles after completion of radiotherapy, 3 wks interval</description>
    <arm_group_label>Radiation Therapy and Chemotherapy</arm_group_label>
    <other_name>Taxol</other_name>
    <other_name>Taxolcarbo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed endometrial carcinoma, with one of the following
             postoperative FIGO 2009 stages and grade:

               1. stage IA with invasion, grade 3 with documented LVSI

               2. stage IB grade 3

               3. stage II

               4. stage IIIA or IIIC; or IIIB if parametrial invasion only

               5. stage IA (with invasion), IB, II, or III with serous or clear cell histology

          -  WHO-performance status 0-2

          -  WBC ≥ 3.0 x 109/L.

          -  Platelets ≥ 100 x 109/L.

          -  Bilirubin ≤ 1.5 x UNL

          -  ASAT/ALAT ≤ 2.5 x UNL

          -  Written informed consent

        Exclusion criteria:

          -  Uterine sarcoma (including carcinosarcoma)

          -  Previous malignancy (except for non-melanomatous skin cancer) &lt; 10 yrs

          -  Previous pelvic radiotherapy

          -  Hormonal therapy or chemotherapy for this tumor

          -  Macroscopic stage II for which Wertheim type hysterectomy (eligible if stage II grade
             3 or stage III at pathology)

          -  Prior diagnosis of Crohn's disease or ulcerative colitis

          -  Residual macroscopic tumor after surgery

          -  Creatinine clearance ≤ 60 ml/min (Cockroft) or ≤ 50 ml/min (EDTA clearance, or
             measured creatinine clearance)

          -  Impaired cardiac function, prohibiting the infusion of large amounts of fluid during
             cisplatin therapy

          -  Peripheral Neuropathy &gt; or = grade 2

          -  Hearing impairment &gt; or = grade 3, or born deaf
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carien L. Creutzberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30120-6/fulltext</url>
    <description>Publication on Toxicity and Quality of life outcomes of the PORTEC-3 trial</description>
  </link>
  <link>
    <url>http://www.msbi.nl/portec3</url>
    <description>trial website (with protocol and all documents)</description>
  </link>
  <link>
    <url>http://scienceblog.cancerresearchuk.org/2010/10/18/joining-forces-against-womb-cancer</url>
    <description>related info with video produced by Cancer Research UK</description>
  </link>
  <reference>
    <citation>Creutzberg CL. Adjuvant chemotherapy for endometrial cancer: unproven. Int J Gynecol Cancer. 2010 Oct;20(7):1105-8. Review.</citation>
    <PMID>21495211</PMID>
  </reference>
  <reference>
    <citation>Jameson MG, McNamara J, Bailey M, Metcalfe PE, Holloway LC, Foo K, Do V, Mileshkin L, Creutzberg CL, Khaw P. Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial. J Med Imaging Radiat Oncol. 2016 Aug;60(4):554-9. doi: 10.1111/1754-9485.12447. Epub 2016 Apr 5.</citation>
    <PMID>27059658</PMID>
  </reference>
  <reference>
    <citation>ANZGOG and PORTEC Group, Blinman P, Mileshkin L, Khaw P, Goss G, Johnson C, Capp A, Brooks S, Wain G, Kolodziej I, Veillard AS, O'Connell R, Creutzberg CL, Stockler MR. Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial. Br J Cancer. 2016 Nov 8;115(10):1179-1185. doi: 10.1038/bjc.2016.323. Epub 2016 Oct 20.</citation>
    <PMID>27764842</PMID>
  </reference>
  <results_reference>
    <citation>de Boer SM, Wortman BG, Bosse T, Powell ME, Singh N, Hollema H, Wilson G, Chowdhury MN, Mileshkin L, Pyman J, Katsaros D, Carinelli S, Fyles A, McLachlin CM, Haie-Meder C, Duvillard P, Nout RA, Verhoeven-Adema KW, Putter H, Creutzberg CL, Smit VTHBM; for PORTEC Study Group. Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer. Ann Oncol. 2018 Feb 1;29(2):424-430. doi: 10.1093/annonc/mdx753.</citation>
    <PMID>29190319</PMID>
  </results_reference>
  <results_reference>
    <citation>de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Kitchener HC, Nijman HW, Kruitwagen RF, Nout RA, Verhoeven-Adema KW, Smit VT, Putter H, Creutzberg CL; PORTEC study group. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2016 Aug;17(8):1114-1126. doi: 10.1016/S1470-2045(16)30120-6. Epub 2016 Jul 7.</citation>
    <PMID>27397040</PMID>
  </results_reference>
  <results_reference>
    <citation>de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC study group. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2. Epub 2018 Feb 12. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.</citation>
    <PMID>29449189</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2006</study_first_submitted>
  <study_first_submitted_qc>December 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2006</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>Carien Creutzberg</investigator_full_name>
    <investigator_title>Chief Investigator</investigator_title>
  </responsible_party>
  <keyword>endometrial clear cell carcinoma</keyword>
  <keyword>stage II endometrial carcinoma</keyword>
  <keyword>stage IA grade 3 endometrial carcinoma</keyword>
  <keyword>stage IB endometrial carcinoma</keyword>
  <keyword>stage IIIA endometrial carcinoma</keyword>
  <keyword>stage IIIB endometrial carcinoma</keyword>
  <keyword>stage IIIC endometrial carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Will be decided with international participating groups at time of final analysis</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

